IBA settles with SK Capital over Molecular unit
BRUSSELS Dec 11 (Reuters) - Belgian cancer therapy group IBA has settled the dispute over the future of its IBA Molecular unit with SK Capital Partners, the group said on Wednesday.
IBA, which develops proton therapy centres that offer more targeted treatment of tumours compared to conventional radiation therapy, had questioned the future financing of the unit which led to claims from SK Capital, which owns 60 percent of IBA Molecular.
As part of the settlement, IBA will sell a 10 million euro ($13.77 million) note it received when it sold the stake for one euro, which will lead to a loss of around 5 million, the group said.
IBA repeated its 2013 guidance for a positive result. ($1 = 0.7261 euros) (Reporting by Robert-Jan Bartunek; editing by Alister Doyle)
- Exclusive: Radar data suggests missing Malaysia plane flown deliberately toward Andamans - sources
- Investigators focus on foul play behind missing plane: sources |
- Search for Malaysian plane may extend to Indian Ocean - U.S |
- Russia blocks internet sites of Putin critics
- Tire blows out on passenger jet taking off from Philadelphia airport